Myla Lai-Goldman

NovoPath LLC is a laboratory information systems company based in Bridgewater, NJ. The company has been recognized for innovation and has developed a SaaS-based platform called NovoPath 360 that enables anatomic and clinical pathology labs worldwide to automate, track, simplify, and complete complex cases from heme to derm faster than ever. NovoPath LIS is the most intuitive and robust laboratory information system that deploys automation, generates insightful patient reports, facilitates workflow adjustments, and helps drive innovation. The CEO of the company is Promise Okeke.

Qvella Corp provides molecular diagnostics. It develops a differentiated technology for pathogen detection by direct sampling of boldily fluids without the need for culturing or time consuming sample processing. The company was founded by Tino Alavie in 2009 and is headquartered in Richmond Hill, Canada.

The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells.

Council for Entrepreneurial Development provides an interactive forum for entrepreneurs, investors, service professionals, academicians, researchers and public policy makers. Its services and programs include connections to capital, venture mentoring, and signature conferences empower member companies to go further. The company was founded in 1984 and is headquartered in Durham, NC.

GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC.

Personalized Science LLC operates as a consulting company. It offers consulting services, The company was founded by Myla Lai-Goldman in 2009 and is headquartered in Chapel Hill, NC.

Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina.